NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,576,965 | -7.5% | 7,684,629 | -10.7% | 0.00% | – |
| Q2 2023 | $4,949,207 | -80.2% | 8,604,322 | -75.8% | 0.00% | -100.0% |
| Q1 2023 | $24,994,391 | -69.2% | 35,558,958 | -1.0% | 0.00% | -66.7% |
| Q4 2022 | $81,203,415 | -27.6% | 35,930,715 | +2.5% | 0.00% | -25.0% |
| Q3 2022 | $112,159,000 | -6.5% | 35,050,519 | +11.0% | 0.00% | 0.0% |
| Q2 2022 | $119,976,000 | -14.8% | 31,572,913 | +20.9% | 0.00% | 0.0% |
| Q1 2022 | $140,757,000 | -60.9% | 26,114,515 | -2.1% | 0.00% | -55.6% |
| Q4 2021 | $360,336,000 | +6.5% | 26,671,803 | +41.5% | 0.01% | 0.0% |
| Q3 2021 | $338,445,000 | +6.1% | 18,844,244 | +1.3% | 0.01% | 0.0% |
| Q2 2021 | $319,111,000 | -16.1% | 18,596,272 | -2.3% | 0.01% | -18.2% |
| Q1 2021 | $380,543,000 | +21.8% | 19,027,136 | +3.5% | 0.01% | +10.0% |
| Q4 2020 | $312,426,000 | +4.8% | 18,378,080 | +2.2% | 0.01% | -9.1% |
| Q3 2020 | $298,224,000 | -31.1% | 17,976,182 | -3.8% | 0.01% | -35.3% |
| Q2 2020 | $432,700,000 | +34.2% | 18,683,127 | +3.4% | 0.02% | +6.2% |
| Q1 2020 | $322,536,000 | -18.9% | 18,069,135 | -1.9% | 0.02% | +6.7% |
| Q4 2019 | $397,543,000 | +61.0% | 18,417,535 | +35.8% | 0.02% | +50.0% |
| Q3 2019 | $246,963,000 | -47.7% | 13,558,280 | +2.2% | 0.01% | -50.0% |
| Q2 2019 | $471,969,000 | +12.2% | 13,264,987 | +6.0% | 0.02% | +5.3% |
| Q1 2019 | $420,516,000 | -1.4% | 12,515,343 | -3.6% | 0.02% | -13.6% |
| Q4 2018 | $426,626,000 | -46.7% | 12,979,178 | -1.1% | 0.02% | -37.1% |
| Q3 2018 | $799,902,000 | +29.4% | 13,121,756 | +3.7% | 0.04% | +25.0% |
| Q2 2018 | $618,118,000 | -59.8% | 12,658,604 | -12.5% | 0.03% | -62.2% |
| Q1 2018 | $1,537,689,000 | +20.1% | 14,471,008 | -32.5% | 0.07% | +21.3% |
| Q4 2017 | $1,279,883,000 | +153.9% | 21,431,388 | +2.1% | 0.06% | +144.0% |
| Q3 2017 | $504,003,000 | +27.5% | 21,000,119 | +3.9% | 0.02% | +19.0% |
| Q2 2017 | $395,330,000 | -15.9% | 20,221,479 | +0.9% | 0.02% | -19.2% |
| Q1 2017 | $470,234,000 | +345660.3% | 20,035,546 | +180432.9% | 0.03% | – |
| Q4 2016 | $136,000 | -38.5% | 11,098 | -13.9% | 0.00% | – |
| Q3 2016 | $221,000 | +33.1% | 12,885 | +10.3% | 0.00% | – |
| Q2 2016 | $166,000 | +33.9% | 11,681 | +29.6% | 0.00% | – |
| Q1 2016 | $124,000 | +42.5% | 9,013 | +74.8% | 0.00% | – |
| Q4 2015 | $87,000 | +163.6% | 5,155 | +72.3% | 0.00% | – |
| Q3 2015 | $33,000 | -23.3% | 2,992 | -13.1% | 0.00% | – |
| Q2 2015 | $43,000 | +7.5% | 3,445 | -6.3% | 0.00% | – |
| Q1 2015 | $40,000 | -29.8% | 3,677 | 0.0% | 0.00% | – |
| Q4 2014 | $57,000 | +26.7% | 3,677 | 0.0% | 0.00% | – |
| Q3 2014 | $45,000 | -4.3% | 3,677 | 0.0% | 0.00% | – |
| Q2 2014 | $47,000 | +2.2% | 3,677 | -2.9% | 0.00% | – |
| Q1 2014 | $46,000 | +12.2% | 3,786 | +4.8% | 0.00% | – |
| Q4 2013 | $41,000 | +5.1% | 3,613 | -3.4% | 0.00% | – |
| Q3 2013 | $39,000 | -4.9% | 3,742 | +4.0% | 0.00% | – |
| Q2 2013 | $41,000 | – | 3,599 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |